Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| B, M, R | ELISA, WB, IHC | Rb | Affinity Purified | Polyclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | AB1632 |
| Brand Family | Chemicon® |
| Trade Name |
|
| Description | Anti-Nitric Oxide Synthase I Antibody |
| Alternate Names |
|
| Product Information | |
|---|---|
| Format | Affinity Purified |
| Presentation | Peptide affinity-purified immunoglobulin. Supplied at a 1mg/mL solution in PBS, pH 7.4, containing 0.1% BSA. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-Nitric Oxide Synthase I Antibody is an antibody against Nitric Oxide Synthase I for use in ELISA, WB, IH. |
| Key Applications |
|
| Application Notes | Immunohistochemistry: Use at 5 - 10 μg/mL on rat neuronal sections fixed with 3.5% paraformaldehyde. Incubation overnight at 4°C with a 1:100 - 1:500 dilution. ABC (peroxidase) detection. Positive staining of Purkinje cells and Layer 5 primary neurons. Western blot: 1 - 10 μg/mL with chemiluminescent detection. Higher concentrations of the antibody may be necessary if colorimetric detection is used. Antibody dilution will also vary with the concentration of antigen. Then antibody should recognize a 155 kDa protein. ELISA: Use at 1.0 μg/mL or lower on plates coated with 50 - 100 ng of peptide antigen. Optimal working dilutions must be determined by the end user. |
| Biological Information | |
|---|---|
| Immunogen | Synthetic peptide corresponding to amino acids 724-739 of human brain NOS, coupled to KLH. |
| Host | Rabbit |
| Specificity | Reactive with human brain NOS-I (nNOS). Antibody binding is neutralized in Western blot by pre-adsorption with the immunogen peptide. This sequence is highly conserved in human, rat and mouse. |
| Species Reactivity |
|
| Antibody Type | Polyclonal Antibody |
| Entrez Gene Number |
|
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P29475 # Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. COFACTOR: Heme group. & Binds 1 FAD. & Binds 1 FMN. & Metrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme. SIZE: 1434 amino acids; 160970 Da SUBUNIT: Homodimer. Interacts with DLG4; the interaction possibly being prevented by the association between NOS1 and CAPON. Forms a ternary complex with CAPON and RASD1. Forms a ternary complex with CAPON and SYN1. Interacts with ZDHHC23. Interacts with NOSIP; which may impair its synaptic location (By similarity). SUBCELLULAR LOCATION: Cell membrane, sarcolemma; Peripheral membrane protein. Cell projection, dendritic spine (By similarity). Note=In skeletal muscle, it is localized beneath the sarcolemma of fast-twitch muscle fiber by associating with the dystrophin glycoprotein complex. In neurons, enriched in dendritic spines (By similarity). TISSUE SPECIFICITY: Isoform 1 is ubiquitously expressed: detected in skeletal muscle and brain, also in testis, lung and kidney, and at low levels in heart, adrenal gland and retina. Not detected in the platelets. Isoform 3 is expressed only in testis. Isoform 4 is detected in testis, skeletal muscle, lung, and kidney, at low levels in the brain, but not in the heart and adrenal gland. DOMAIN: SwissProt: P29475 The PDZ domain in the N-terminal part of the neuronal isoform participates in protein-protein interaction, and is responsible for targeting nNos to synaptic membranes in muscles (By similarity). DISEASE: SwissProt: P29475 # Genetic variations in NOS1 gene are associated with susceptibility to infantile hypertrophic pyloric stenosis type 1 (IHPS1) [MIM:179010]. IHPS has an incidence of 1-5 per 1000 live births in whites and a marked preponderance of males to females (4:1). IHPS is the most frequent disorder requiring surgery in the first year of life. The disorder is characterized by hypertrophy and hyperplasia of the circular muscle layer of the pylorus, leading to persistent vomiting 2-12 weeks after birth. Defective pyloric relaxation and increased pyloric smooth muscle mass have been suggested to be responsible for gastric-outlet obstruction. SIMILARITY: Belongs to the NOS family. & Contains 1 flavodoxin-like domain. & Contains 1 PDZ (DHR) domain. |
| Product Usage Statements | |
|---|---|
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated thawing and refreezing. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |